ZYBERNO
Stock Report
Updated Sep 1, 2026

IGC PHARMA, INC. (IGC)

Healthcare • NYSE

$0.30

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
22.0/100
POOR BUSINESS
IGC PHARMA, INC. (IGC) scores 22/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.06x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-94.7%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

IGC PHARMA, INC. (IGC) stock report — Zyberno Score 22/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.30
Market Cap:$30.02M

Valuation Multiples (3)

P/B Ratio:4.90x
P/S Ratio:34.54x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$30.02M

Price Action & Momentum (3)

Momentum Percentile:26 / 100
% of 52-Week High:63.7%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:4.7%
Fundamental Growth Rate (g):-4.5%

Margin Analysis (1)

Ebitda Margin:-854.0%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:30.7%
Latest Earnings Filed:2022-02-10

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):19.9%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:0.39x
Quick Ratio:0.19x
Cash Ratio:0.10x

Leverage Analysis (3)

Debt To Equity Ttm:0.06x
Debt-to-Equity Ratio:0.06x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-1,936.25x
Times Interest Earned:-1,936.25

Capital Structure (4)

Working Capital:-1,951,000.00
Cash And Cash Equivalents:331,000.00
Long Term Debt:$131.00K
Net Debt:$0.00
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $869.00K
Linear Growth: 19.9%
📊 Click to view full IGC Revenue analysis & methodology →
Cost Of Revenue Ttm:$572.00K

Profitability Breakdown (2)

Gross profit TTM: $297.00K
Linear Growth: -1.7%
📊 Click to view full IGC Gross Profit analysis & methodology →
-$7.75M

Bottom Line Performance (3)

-$4.15M
Income Before Tax:-$9.48M
Ebitda Ttm:-7,421,000.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:4,777,000.00
Sga Expense:4,093,000.00
Income Tax Expense:$0.00
Interest Expense:4,000.00

Expense Ratios (3)

R And D To Revenue Percentage:1,802.6%
Sga To Revenue Percentage:1,544.5%
Ebitda Margin:-854.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$9.50M
Current Assets:$1.26M
Ppe Net:2,069,000.00
Goodwill:0.00
Intangible Assets:$5.51M

Liability Structure (4)

Total Liabilities:3,364,000.00
Current Liabilities:3,215,000.00
Long Term Debt:$131.00K
Short Term Debt:$200.00K

Equity & Capital (3)

Equity:$6.13M
Retained Earnings:-$130.23M
Common Stock:600,000,000.00

Working Capital Items (3)

Accounts Receivable:56,000.00
Inventory:640,000.00
Accounts Payable:1,618,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:4,000,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$4.72M-$4.77M

Investment Activities (1)

Investing Cash Flow:-$170.00K

Financing Activities (3)

Financing Cash Flow:$710.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:87,000.00
Long Term Debt Issuance:$623.00K
Long Term Debt Repayments:$1.00K
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.04

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.01
Operating Cash Flow Per Share:-$0.05

Book Value & Capital (2)

Book Value Per Share:$0.06
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.09x
Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:15.52x
Days Sales Outstanding Ttm:23.52

Inventory Management (2)

Inventory Turnover Ttm:0.89x
Days Inventory Outstanding Ttm:408.39

Payables & Cash Cycle (2)

Days Payable Outstanding:1,032.47
Cash Conversion Cycle:-600.55
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:4.7%
Fundamental Growth Rate (g):-4.5%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):19.9%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-1.7%
Book Value Growth Rate (Linear):-25.6%
C. Company Profile & Context

Corporate Information (6)

Symbol:IGC
Company Name:IGC PHARMA, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NYSE
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:100.33M
Shares Outstanding Basic:100.33M
Shares Outstanding Diluted:100.33M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 08:38:06 UTC
Data Timestamp:2026-08-20T21:51:47.459094
Scroll to Top